Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments
Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs Lexaria has so far shown that its DehydraTECH-CBD is…